Looking to read the full article? Subscribe to BioWorld Asia.

Azura Ophthalmics raises $20M series C for registration study in Meibomian gland dysfunction

October 27, 2020

PERTH, Australia – Azura Ophthalmics Ltd. raised a $20 million series C round with existing investors, including Brandon Capital’s Medical Research Commercialization Fund (MRCF), Orbimed, TPG Biotech and Ganot Capital.

BioWorld Asia Financings Ocular Series C Australia

Already a subscriber? Sign in

Today's news in brief

BioWorld

BioWorld briefs for Nov. 24.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for Nov. 24.

Desperately seeking wellness and immunity in a sea of COVID-19 research

BioWorld

October brought another burgeoning swell of pandemic news with the U.S. granting its first FDA approval for a COVID-19 therapy, a promising vaccine candidate...

Lucira Health wins FDA nod for first completely in-home COVID-19 test

BioWorld MedTech

Lucira Health Inc. has secured U.S. FDA emergency use authorization for the first prescription molecular diagnostic test for COVID-19 that can be performed from...

Seed Therapeutics blossoms in an $800M deal with Lilly

BioWorld

Seed Therapeutics Inc. signed a massive deal with Eli Lilly and Co. on Nov. 12, a date that resonated deeply with Seed’s CEO, Lan Huang. Twenty-one years earlier...